JNK V demonstrated a dose-dependent reduction in the proliferation of T-cell acute lymphoblastic leukaemia (T-ALL) cells by inducing apoptosis and cell cycle arrest, accompanied by a reduction in c-Myc and Bcl-2 protein levels [72]. The gene discussed is BCL2; the disease is T-cell acute lymphoblastic leukemia.